Novartis (NOVN) Given a CHF 84 Price Target by JPMorgan Chase & Co. Analysts

Novartis (VTX:NOVN) received a CHF 84 price objective from JPMorgan Chase & Co. in a research report issued to clients and investors on Thursday. The brokerage currently has a “neutral” rating on the stock. JPMorgan Chase & Co.’s target price suggests a potential downside of 0.10% from the stock’s current price.

NOVN has been the subject of several other reports. set a CHF 90 target price on shares of Novartis and gave the company a “buy” rating in a research note on Tuesday, September 19th. Baader Bank set a CHF 90 target price on shares of Novartis and gave the company a “buy” rating in a research note on Monday, October 30th. Berenberg Bank set a CHF 88 price target on shares of Novartis and gave the company a “neutral” rating in a report on Monday, October 30th. Sanford C. Bernstein set a CHF 97 price target on shares of Novartis and gave the company a “buy” rating in a report on Thursday, October 26th. Finally, Societe Generale set a CHF 95 price target on shares of Novartis and gave the company a “buy” rating in a report on Wednesday, October 25th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of CHF 86.97.

Shares of Novartis (VTX:NOVN) opened at CHF 84.08 on Thursday. Novartis has a one year low of CHF 69.50 and a one year high of CHF 85.40. The stock has a market cap of $219,460.00 and a PE ratio of 30.69.

TRADEMARK VIOLATION NOTICE: “Novartis (NOVN) Given a CHF 84 Price Target by JPMorgan Chase & Co. Analysts” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.com-unik.info/2018/01/06/novartis-novn-given-a-chf-84-price-target-by-jpmorgan-chase-co-analysts.html.

Novartis Company Profile

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit